GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Enclosed please find herewith the details of Earnings Call slated for Friday, August 12, 2022 at 8:30 a.m. - 9:30 a.m. (1ST), for your information and record. GLENMARK PHARMACEUTICALS LTD. - 532296 - Closure of Trading Window
We have to inform you that, pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, a meeting of the Board of Directors will be held on Wednesday, August 10, 2022, inter alia, to consider and approve the Unaudited Financial Results of the Company for the first quarter ended June 30, 2022. Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from June 30, 2022 to August 12, 2022 (both days inclusive) for the purpose of approval of Unaudited Financial Results for the First quarter ended June 30, 2022. GLENMARK PHARMACEUTICALS LTD. - 532296 - Board Meeting Intimation for Unaudited Financial Results Of The Company For The First Quarter Ended June 30, 2022.
GLENMARK PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2022 ,inter alia, to consider and approve We have to inform you that, pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, a meeting of the Board of Directors will be held on Wednesday, August 10, 2022, inter alia, to consider and approve the Unaudited Financial Results of the Company for the first quarter ended June 30, 2022. Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from June 30, 2022 to August 12, 2022 (both days inclusive) for the purpose of approval of Unaudited Financial Results for the First quarter ended June 30, 2022.
Glenmark Pharma arm gets final USFDA nod for birth control capsules
The approval granted by the US Food Drug Administration (USFDA) to Glenmark Pharmaceuticals Inc is for Norethindrone Acetate and Ethinyl Estradiol Capsules and Ferrous Fumarate Capsules of strength 1 mg/20 mcg, the company said in a statement. GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark Pharmaceuticals receives ANDA approval for Norethindrone Acetate and Ethinyl Estradiol Capsules and Ferrous Fumarate Capsules, 1 mg/20 mcg GLENMARK PHARMACEUTICALS LTD. - 532296 - Statement Of Investor Complaints For The Quarter Ended June 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0110 Name of the Signatory :- Harish KuberDesignation :- Company Secretary and Compliance Officer GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark Pharmaceuticals and SaNOtize Announce Peer Reviewed Publication of Its Phase 3 Clinical Trials on SaNOtize''s Novel Nitric Oxide Nasal Spray for COVID-19 in Lancet Journal GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark Pharmaceuticals launches MINYM(r) GEL - India's First Topical Minocycline 4% Gel for the Treatment of Moderate to Severe Acne GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark launches Sitagliptin and its Fixed Dose Combinations, at Affordable Price for Adults with Type 2 Diabetes in India GLENMARK PHARMACEUTICALS LTD. - 532296 - U.S. FDA Inspection At The Company''s Aurangabad, India Facility
U.S. FDA inspection at the Company''s Aurangabad, India Facility